Literature DB >> 7285305

Prostaglandin E1 infants with ductus arteriosus-dependent congenital heart disease.

M D Freed, M A Heymann, A B Lewis, S L Roehl, R C Kensey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7285305     DOI： 10.1161/01.cir.64.5.899

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  42 in total

1.  Effectiveness of prostaglandin E1 in relieving obstruction in coarctation of the aorta without opening the ductus arteriosus.

Authors:  L Liberman; W M Gersony; P A Flynn; J J Lamberti; R S Cooper; T J Stare
Journal:  Pediatr Cardiol       Date:  2004 Jan-Feb       Impact factor: 1.655

2.  Detecting congenital heart disease prenatally.

Authors:  G C Smith
Journal:  BMJ       Date:  1992-04-18

Review 3.  The neonate with congenital heart disease: diagnosis and management.

Authors:  B Chandramouli
Journal:  Indian J Pediatr       Date:  1991 Jul-Aug       Impact factor: 1.967

Review 4.  Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins.

Authors:  Elaine L Shelton; Gautam K Singh; Colin G Nichols
Journal:  Semin Perinatol       Date:  2018-05-10       Impact factor: 3.300

5.  Formation of biologically active 13,14-dihydro-prostaglandin E1 during intravenous infusion of prostaglandin E1 in newborns with ductus arteriosus-dependent congenital heart disease.

Authors:  A Leonhardt; H Schweer; D Wolf; H W Seyberth
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

Review 6.  Prostaglandin E1: first stage palliation in neonates with congenital cardiac defects.

Authors:  S C Reddy; A Saxena
Journal:  Indian J Pediatr       Date:  1998 Mar-Apr       Impact factor: 1.967

7.  Use of prostaglandin E2 in management of transposition of great arteries before balloon atrial septostomy.

Authors:  A Beitzke; C H Suppan
Journal:  Br Heart J       Date:  1983-04

8.  Prostaglandin Availability and Association with Outcomes for Infants with Congenital Heart Disease.

Authors:  Brady S Moffett; Joshua M Garrison; Aimee Hang; Shaine A Morris; Rocky Tsang; Kimberly Dinh; Pamela Griffiths; Ronald Bronicki; Paul A Checchia
Journal:  Pediatr Cardiol       Date:  2015-10-24       Impact factor: 1.655

9.  Responses of the post-term arterial duct to oxygen, prostaglandin E2, and the nitric oxide donor, 3-morpholinosydnonimine, in lambs and their clinical implications.

Authors:  S E Abrams; K P Walsh; S J Coker; M J Clarkson
Journal:  Br Heart J       Date:  1995-02

10.  Prostaglandin E2 administration in infants with ductus-dependent cyanotic congenital heart disease.

Authors:  B D Thanopoulos; A Andreou; C Frimas
Journal:  Eur J Pediatr       Date:  1987-05       Impact factor: 3.183
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.